title: Magnetic resonance imaging contrast agents.
abstract: Intravenous contrast enhancement has assumed a prominent position in clinical MR imaging, particularly for studies of the head and spine. New chelates such as gadoteridol are likely to be approved in the near future; gadopentetate dimeglumine is the only agent approved for clinical use in the United States. Clinical applications have rapidly expanded for the gadolinium chelates with extracellular distribution. Within the next decade, approval is anticipated for a variety of additional agents that may help assess tissue function.
authors.forename: V M
authors.initials: VM
authors.lastname: Runge
mesh_terms: D000005:Abdomen / Q000473:pathology; D000818:Animals; D001927:Brain Diseases / Q000175:diagnosis; D003287:Contrast Media; D004338:Drug Combinations; D005682:Gadolinium; D019786:Gadolinium DTPA; D006571:Heterocyclic Compounds; D006801:Humans; D008107:Liver Diseases / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D008536:Meglumine; D009942:Organometallic Compounds; D004369:Pentetic Acid; D013122:Spinal Diseases / Q000175:diagnosis
chemical_list: D003287:Contrast Media; D004338:Drug Combinations; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA